Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells
Petra Gener(CIBBIM-Nanomedicine), Simó Schwartz(CIBBIM-Nanomedicine), Joan Sayós(Beth Israel Deaconess Medical Center), Guillem Romero Sabat(Vall d'Hebron Institut de Recerca), Ibane Abasolo(Universitat Autònoma de Barcelona), Alexandra Arranja(University of Lisbon), Diego Arango(Universitat Autònoma de Barcelona), Núria Bergadà Fort(Vall d'Hebron Institut de Recerca), Yolanda Fernández(CIBBIM-Nanomedicine), Mafalda Videira(University of Lisbon), Rafael Miñana Prieto(Vall d'Hebron Institut de Recerca), Diana Rafael(University of Lisbon)
Cited by 85
Related Papers
The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM
|Nature|1998|942
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
|British Journal of Cancer|2004|275
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
|Advanced Drug Delivery Reviews|2013|237
Immune system targeting by biodegradable nanoparticles for cancer vaccines
|Journal of Controlled Release|2013|229
Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles
|Journal of drug targeting|2002|210